XML 52 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Restructuring, Impairment, and Related Charges, Net (Tables)
 12 Months Ended
Mar. 31, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Details for Charges Recorded
Restructuring, impairment, and related charges, net for the year ended March 31, 2026 consisted of the following:
Year Ended March 31, 2026
(In millions)
North American Pharmaceutical (1)
Prescription Technology Solutions (2)
Medical-Surgical Solutions (3)
Corporate & Other (4)
Total
Severance and employee-related costs, net$9 $3 $14 $(1)$25 
Exit and other-related costs (5)
3 — 37 151 191 
Asset impairments and accelerated depreciation12 17 (8)8 29 
Total$24 $20 $43 $158 $245 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment.
(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Prescription Technology Solutions segment.
(3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.
(4)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate and other activities.
(5)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Fiscal 2025
Restructuring, impairment, and related charges, net for the year ended March 31, 2025 consisted of the following:
Year Ended March 31, 2025
(In millions)
North American Pharmaceutical (1)
Oncology & MultispecialtyPrescription Technology Solutions
Medical-Surgical Solutions (2)
Corporate & Other (3)
Total
Severance and employee-related costs, net$(3)$1 $— $137 $3 $138 
Exit and other-related costs (4)
3 — 3 53 49 108 
Asset impairments and accelerated depreciation 59 — 9 14 16 98 
Total$59 $1 $12 $204 $68 $344 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment charge of $58 million within "Cost of sales" in the Consolidated Statement of Operations.
(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment.
(3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate and other activities.
(4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Fiscal 2024
Restructuring, impairment, and related charges, net for the year ended March 31, 2024 consisted of the following:
Year Ended March 31, 2024
(In millions)
North American Pharmaceutical (1)
Oncology & Multispecialty(1)
Prescription Technology SolutionsMedical-Surgical Solutions
Corporate & Other (1)(2)
Total
Severance and employee-related costs, net$7 $5 $— $(1)$(1)$10 
Exit and other-related costs (3)
3 1 11 12 35 62 
Asset impairments and accelerated depreciation
10 3 — — 30 43 
Total$20 $9 $11 $11 $64 $115 
(1)Includes costs related to operational efficiencies and cost optimization efforts to support the Company’s North American Pharmaceutical, Oncology & Multispecialty, Corporate and other activities.
(2)Corporate & other includes costs for business transformation and optimization efforts related to the Company’s technology organization and costs related to the Company’s divested European operations.
(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Restructuring Reserve by Type of Cost
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2026 and 2025:
(In millions)North American PharmaceuticalOncology & MultispecialtyPrescription Technology SolutionsMedical-Surgical Solutions
Corporate & Other
Total
Balance, March 31, 2024 (1)
$23 $3 $5 $1 $23 $55 
Restructuring, impairment, and related charges, net591 12 204 68 344
Non-cash charges(58)(1)(9)(14)(16)(98)
Cash payments(8)(2)(4)(99)(51)(164)
Other (2)
(5)(1)(3)(2)— (11)
Balance, March 31, 2025 (3)
11 — 1 90 24 126 
Restructuring, impairment, and related charges, net24 — 20 43 158 245 
Non-cash charges(12)— (17)8 (8)(29)
Cash payments(4)— (1)(133)(161)(299)
Other (2)
(1)— — 2 — 1 
Balance, March 31, 2026 (4)
$18 $— $3 $10 $13 $44 
(1)    As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.
(2)    Other primarily includes cumulative translation adjustments as well as adjustments to Canadian retail disposal group reserves within North American Pharmaceutical segment in fiscal 2025, and transfers to certain other liabilities for the remaining segments.
(3)    As of March 31, 2025, the total reserve balance was $126 million, of which $103 million was recorded in “Other accrued liabilities” and $23 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.
(4)    As of March 31, 2026, the total reserve balance was $44 million, of which $30 million was recorded in “Other accrued liabilities” and $14 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheet.